Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients
- PMID: 16230042
- DOI: 10.1016/j.ghir.2005.08.005
Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients
Abstract
Prader-Willi syndrome (PWS) is a complex genetic disease, clinically characterised by short stature, abnormal body composition, with more body fat than lean body mass, hyperphagia and obesity. Partial growth hormone (GH) deficiency is common, and GH treatment to PWS children and adults has shown beneficial effects on body composition. In this study, we have evaluated indices of GH's lipolytic effect in 6 PWS adults analysing glycerol, lactate and glucose in dialysate from microdialysis in subcutaneous abdominal adipose tissue. The patients were four men and two women, 19-37 years old; all hypogonadal. BMI was 24.2-49.1, mean 35.9 kg/m(2). All had normal serum insulin levels. They received GH therapy (Genotropin Pfizer) during 12 months and doses were individually titrated to normal serum IGF-I for age. Immediately before treatment start and at 12 months, 30-36 h after the last GH injection, sampling of dialysate was carried out at night (11 p.m. to 7 a.m.), as well as after intravenously injection of a standardised GH dose (0.8 mg). At baseline individual mean night time glycerol and lactate were similar to levels in adults without PWS (160.7-278.1 micromol/L and 0.80-3.99 mmol/L, respectively), and did not change with 12 months GH treatment. Glucose levels were normal, except in a patient with diabetes, and did not change during the study. Compared to baseline the immediate effect of GH injection resulted in a significant increase in glycerol levels after 12 months. In conclusion, night time lipolytic response in this small group of PWS adults seemed normal and did not change after 12 months GH treatment. On the other hand short-term GH induced lipolysis increased, indicating normal lipolytic response in PWS.
Similar articles
-
Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.J Intellect Disabil Res. 2005 Apr;49(Pt 4):245-52. doi: 10.1111/j.1365-2788.2005.00641.x. J Intellect Disabil Res. 2005. PMID: 15816811 Clinical Trial.
-
Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome.Growth Horm IGF Res. 2010 Jun;20(3):179-84. doi: 10.1016/j.ghir.2009.12.004. Epub 2010 Mar 3. Growth Horm IGF Res. 2010. PMID: 20199883 Clinical Trial.
-
Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.Clin Endocrinol (Oxf). 2008 Sep;69(3):443-51. doi: 10.1111/j.1365-2265.2008.03228.x. Epub 2008 Mar 18. Clin Endocrinol (Oxf). 2008. PMID: 18363884 Clinical Trial.
-
Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.J Pediatr Endocrinol Metab. 2004 Sep;17 Suppl 4:1297-306. J Pediatr Endocrinol Metab. 2004. PMID: 15506076 Review.
-
Prader-Willi syndrome: how does growth hormone affect body composition and physical function?J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1445-51. J Pediatr Endocrinol Metab. 2001. PMID: 11837498 Review.
Cited by
-
Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment.Int J Obes (Lond). 2014 Sep;38(9):1234-40. doi: 10.1038/ijo.2014.3. Epub 2014 Jan 10. Int J Obes (Lond). 2014. PMID: 24406482
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical